Merck reported Phase 2 CADENCE results showing WINREVAIR met the primary endpoint in adults with CpcPH-HFpEF. The company said the data support advancement into a registrational Phase 3 study.
AI-powered clinical alerts improved heart valve disease treatment rates by 40% in a multicenter trial involving 35 hospitals. The system increased timely interventions and reduced disparities in care access across different patient populations.
Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.
Arrowhead Pharmaceuticals presented long-term data showing plozasiran achieved 83% median triglyceride reduction in severe hypertriglyceridemia patients with no acute pancreatitis events over two years. The RNA interference therapy demonstrated durable improvements in atherogenic lipoproteins and consistent safety profile. The company plans to complete Phase 3 studies by mid-2026 and submit for regulatory approval.
A new study of over 246,000 heart disease patients shows the shingles vaccine reduces major cardiovascular events by 46% and death by 61% within one year. The protective effects are comparable to quitting smoking and support existing vaccine recommendations for adults over 50. The findings will be presented at the American College of Cardiology's annual meeting.
Merck will present late-breaking clinical data from its cardio-pulmonary pipeline at ACC.26, including positive Phase 3 results for enlicitide, an investigational oral PCSK9 inhibitor, and Phase 2 data for WINREVAIR in heart failure patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05948969 |
Transform CV Risk in Diabetes |
UNKNOWN | NA |
| NCT05572814 |
Transform: Teaching, Technology, and Teams |
UNKNOWN | NA |
| NCT05504356 |
Volunteers to Investigate Best Results for Ablation and Novel Therapies for Atrial Fibrillation |
RECRUITING | |
| NCT05245747 |
Vitls Feasibility Physiologic Monitoring |
COMPLETED | |
| NCT05117086 |
DASH Diet in Heart Failure Outpatients |
ACTIVE_NOT_RECRUITING | NA |
| NCT04872959 |
TRANSFORM Heart Failure with Reduced Ejection Fraction |
WITHDRAWN | NA |
| NCT03492788 |
Optimizing CRT With ECGI |
TERMINATED | NA |
| NCT02919982 |
Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation |
COMPLETED | |
| NCT02699957 |
Left Atrial Appendage Occlusion Registry (LAAO Registry) |
RECRUITING | |
| NCT02635477 |
Get Going: Accelerometer-Based Intervention to Promote Physical Activity in Frail Older Adults |
UNKNOWN | NA |
